Search the dictionary

#

• 95% Confidence IntervalClinical Trial Endpoints and Statistical AnalysisAn interval produced by a method that, under its assumptions, would contain the true parameter in 95% of repeated samples. In a clinical trial report, it illustrates the uncertainty around an estimate and should be interpreted together with the effect size and analysis method.

A

• AAV Gene Therapy Antibody Testing (Pre-existing Antibodies)DMD Treatment and Therapeutic ApproachesAn antibody test in the context of Duchenne muscular dystrophy (DMD) generally refers to one of two different applications: AAV gene therapy antibody testing or dystrophin protein analysis (monoclonal antibodies).
• Absolute ChangeClinical Trial Endpoints and Statistical AnalysisThe numerical difference between a measurement at a follow-up visit and its baseline value. For example, a participant's NSAA score may change from 20 to 22, representing an absolute increase of two points, although the meaning of that change depends on the clinical context.
• Accelerated ApprovalRegulatory and Drug Development TerminologyA regulatory pathway that may allow earlier approval of a treatment for a serious condition based on a surrogate or intermediate clinical endpoint reasonably likely to predict benefit, where applicable requirements are met. It may require confirmatory studies to verify clinical benefit.
• Active ComparatorClinical Trial Design and Research TerminologyAn established treatment used as a comparison against an investigational intervention in a clinical trial. In DMD research, an active comparator may help researchers assess relative effectiveness or safety, depending on the study design and the accepted standard of care.
• Adeno-Associated Virus (AAV)DMD Genetics and Molecular BiologyA small virus-derived vector commonly engineered to deliver genetic material into cells. AAV vectors are used in some DMD gene therapy programs to deliver microdystrophin instructions, although immune responses, limited cargo capacity, and other safety considerations affect their use.
• Adverse Drug Reaction (ADR)Safety and Adverse Event TerminologyAn unwanted and harmful response for which there is at least a reasonable possibility of a causal relationship with a medicinal product. In DMD trials, suspected adverse drug reactions require careful assessment because participants may also experience complications related to the underlying disease.
• Adverse Event (AE)Safety and Adverse Event TerminologyAny unfavorable medical occurrence in a participant during a clinical study, whether or not it is considered related to the investigational treatment. DMD trial reports should describe adverse events by type, severity, frequency, timing, and the assessment of their relationship to treatment.
• Adverse Event of Special Interest (AESI)Safety and Adverse Event TerminologyAn adverse event or medical condition that requires particular attention because of a treatment's mechanism, known risks, or emerging safety concerns. In DMD trials, predefined events of special interest may receive enhanced monitoring and targeted reporting procedures.
• Aggregate DataClinical Trial Data, Access, and ReportingInformation summarized across a group of participants rather than presented separately for each individual. DMD trial publications commonly report aggregate measures such as mean NSAA scores, average CK levels, or adverse-event frequencies, which can be useful but may conceal individual differences.
• Alanine Aminotransferase (ALT)Biomarkers and Laboratory MeasurementsAn enzyme commonly used to assess liver injury that can also enter the bloodstream from damaged skeletal muscle. In DMD, ALT may be elevated because of muscle disease, making it important to interpret the result alongside CK, other laboratory tests, and clinical context.
• Allocation RatioClinical Trial Design and Research TerminologyThe proportion of participants assigned to each study arm. For example, a 2:1 allocation ratio means that approximately twice as many participants are assigned to one group as to the other, subject to the study's design and actual enrollment.
• AmbulatoryDuchenne Muscular Dystrophy: Disease TerminologyA term describing a person's ability to walk independently. In DMD research, ambulatory participants can perform walking-related assessments, while non-ambulatory participants have lost the ability to walk independently and require different functional outcome measures.
• Anti-Drug Antibodies (ADAs)Safety and Adverse Event TerminologyAntibodies produced by the immune system that recognize a therapeutic product as a target. In DMD studies, anti-drug antibodies may affect a treatment's activity, clearance, or safety, although their clinical importance depends on antibody characteristics and the specific treatment involved.
• Anti-Inflammatory TherapyDMD Treatment and Therapeutic ApproachesA treatment intended to reduce inflammatory processes that contribute to tissue injury or symptoms. In DMD, inflammation accompanies ongoing muscle damage, and anti-inflammatory approaches may help manage disease-related processes, although the clinical benefit depends on the specific treatment and evidence.
• Antisense Oligonucleotide (ASO)DMD Treatment and Therapeutic ApproachesA short, synthetic strand of nucleic acid designed to bind a selected RNA sequence and alter its processing or activity. In DMD, some antisense oligonucleotides target specific exons to promote exon skipping and potentially restore the dystrophin reading frame.
• Aspartate Aminotransferase (AST)Biomarkers and Laboratory MeasurementsAn enzyme found in several tissues, including skeletal muscle, heart, and liver. AST levels can be elevated in DMD because of muscle damage, so an increased result does not necessarily indicate primary liver disease and should be interpreted alongside other clinical findings.
• AssentClinical Trial Design and Research TerminologyAn affirmative agreement to participate in research provided by a child or another person who cannot legally provide full informed consent independently. In pediatric DMD trials, assent is sought when appropriate alongside permission from a parent or legally authorized representative.

B

• Baseline BiomarkerBiomarkers and Laboratory MeasurementsA biological measurement collected before treatment begins or before the relevant study intervention. In DMD clinical trials, baseline CK, dystrophin, or imaging results can help characterize participants and provide a reference point for evaluating changes after treatment.
• Baseline CharacteristicsClinical Trial Data, Access, and ReportingThe demographic, genetic, clinical, and functional features of participants measured before treatment or at the study's defined starting point. In DMD trials, these characteristics help readers assess whether treatment and control groups are comparable and whether results apply to other patient populations.
• Becker Muscular Dystrophy (BMD)Duchenne Muscular Dystrophy: Disease TerminologyA genetic muscle disorder caused by DMD gene mutations that allow some functional dystrophin to be produced. Symptoms are generally milder and progress more slowly than in Duchenne muscular dystrophy, although severity varies considerably between individuals.
• Benefit-Risk ProfileAdvanced Clinical Research and Emerging Treatment ConceptsThe overall assessment of a treatment's potential advantages compared with its known and potential harms. In DMD, evaluating this profile requires consideration of disease severity, the magnitude and durability of benefit, adverse events, alternative treatments, and uncertainty in the available evidence.
• Between-Group DifferenceClinical Trial Endpoints and Statistical AnalysisThe difference in an outcome between two or more study groups at a specified time point or over a defined period. In DMD trials, comparing treatment and control groups helps estimate whether observed changes exceed those expected from natural disease progression or other factors.
• Biological ActivityAdvanced Clinical Research and Emerging Treatment ConceptsA measurable effect of a treatment on a biological system, such as a change in protein expression or molecular signaling. In DMD, evidence of biological activity can support a treatment's proposed mechanism, but additional evidence is generally needed to establish meaningful clinical benefit.
• Biologics License Application (BLA)Regulatory and Drug Development TerminologyA regulatory application submitted to the US FDA seeking permission to market a biological product. For relevant DMD therapies, a BLA includes evidence concerning manufacturing, quality, safety, and effectiveness, together with other information required for regulatory assessment.
• BiomarkerBiomarkers and Laboratory MeasurementsA measurable biological characteristic that provides information about a normal process, disease process, or response to treatment. In DMD, biomarkers include creatine kinase, liver-associated enzymes, dystrophin levels, and imaging measurements used to assess muscle damage or treatment effects.
• Biomarker EndpointBiomarkers and Laboratory MeasurementsA clinical trial endpoint based on a measurable biological characteristic rather than a direct assessment of how a patient feels, functions, or survives. In DMD, examples may include dystrophin levels or laboratory measurements, but their ability to predict clinical benefit must be established for the intended use.
• Biomarker VariabilityBiomarkers and Laboratory MeasurementsThe natural or measurement-related differences observed when a biomarker is assessed across individuals or at different times. In DMD studies, activity, age, disease stage, sample handling, and laboratory methods can influence results and complicate comparisons between participants or trials.
• Bone Mineral Density (BMD)Respiratory, Cardiac, and Musculoskeletal TerminologyA measurement of the amount of mineral contained in bone, commonly assessed using imaging methods such as dual-energy X-ray absorptiometry. In DMD, reduced mobility and corticosteroid exposure can contribute to low bone mineral density and increased fracture risk.
• Breakthrough Therapy DesignationRegulatory and Drug Development TerminologyA US regulatory designation intended to expedite the development and review of a treatment for a serious condition when preliminary clinical evidence indicates substantial improvement over available therapy on clinically significant endpoints. It does not establish definitive effectiveness or guarantee approval.

C

• Cardiac MRIRespiratory, Cardiac, and Musculoskeletal TerminologyA magnetic resonance imaging examination used to evaluate the structure and tissue characteristics of the heart. In DMD, cardiac MRI can help identify abnormalities such as myocardial fibrosis and assess cardiac involvement, sometimes detecting changes before conventional measures show substantial impairment.
• CardiomyopathySafety and Adverse Event TerminologyA disease of the heart muscle that can impair its ability to pump blood effectively. DMD-associated cardiomyopathy may develop as dystrophin deficiency damages cardiac muscle, making cardiac monitoring an important component of both routine care and clinical trial safety assessments.
• Cardiomyopathy MonitoringRespiratory, Cardiac, and Musculoskeletal TerminologyThe ongoing assessment of heart structure and function in people at risk of or living with heart muscle disease. In DMD, monitoring may include cardiac imaging, electrocardiograms, and clinical evaluations to detect abnormalities and guide appropriate cardiac management.
• Caregiver-Reported Outcome (CRO)Clinical Trial Endpoints and Statistical AnalysisA measure based on information reported by a caregiver about a participant's health, symptoms, or daily functioning. In pediatric DMD research, caregiver reports can provide useful insight into everyday experiences, but they are distinct from direct patient reports and clinician assessments.
• Causality AssessmentSafety and Adverse Event TerminologyThe process of evaluating whether an adverse event may have been caused by a treatment or another factor. In DMD trials, causality assessments consider timing, biological plausibility, alternative explanations, dose relationships, and available clinical evidence, while acknowledging uncertainty.
• Cell TherapyDMD Treatment and Therapeutic ApproachesA treatment approach that uses living cells to produce a therapeutic effect, such as supporting tissue repair or modifying biological processes. In DMD research, cell-based strategies are being investigated for muscle regeneration and other potential benefits, but delivery, cell survival, safety, and effectiveness remain key challenges.
• Change from BaselineClinical Trial Endpoints and Statistical AnalysisThe difference between a participant's measurement before treatment and the corresponding measurement at a later time point. DMD trials commonly report change from baseline in functional scores, biomarkers, and imaging measures to assess how outcomes evolve during treatment.
• Clinical EndpointBiomarkers and Laboratory MeasurementsA predefined outcome used to evaluate a treatment's effects on patients' health, function, or survival. In DMD trials, clinical endpoints may include changes in motor assessments, the time until loss of ambulation, respiratory outcomes, or other measures relevant to patients.
• Clinical Outcome Assessment (COA)Clinical Trial Endpoints and Statistical AnalysisAn instrument or method used to evaluate how a participant feels, functions, or survives. In DMD trials, clinical outcome assessments may include performance-based motor tests, patient-reported measures, clinician assessments, or caregiver reports, depending on the study's objectives.
• Clinical StudyClinical Trial Design and Research TerminologyA research investigation designed to collect information about health, disease, or medical interventions in people. In DMD, clinical studies may evaluate disease progression, genetic characteristics, treatment safety, biomarkers, or clinical outcomes and may be interventional or observational.
• Clinical Study Report (CSR)Clinical Trial Endpoints and Statistical AnalysisA detailed technical document describing a clinical trial's design, methods, results, and statistical analyses. A complete report can provide more information than a brief press release, helping researchers evaluate safety findings, participant characteristics, endpoints, and limitations.
• Clinical TrialClinical Trial Design and Research TerminologyA research study involving human participants that evaluates a medical intervention, such as a drug, gene therapy, or other treatment. DMD clinical trials investigate safety, dosage, biological activity, and whether a treatment improves outcomes compared with a suitable alternative.
• Clinical Trial IdentifierClinical Trial Data, Access, and ReportingA unique identifier assigned to a clinical study in a registry or research system. For example, an NCT number identifies a record on ClinicalTrials.gov, allowing readers to locate the study protocol, eligibility requirements, participating sites, and available updates.
• Clinical Trial PhaseClinical Trial Design and Research TerminologyA classification describing the stage of clinical development and the main objectives of a study. DMD programs may progress through Phase 1, Phase 2, and Phase 3 trials, although study designs can overlap in their objectives and do not guarantee successful approval.
• Clinically Meaningful ChangeNSAA and Functional Assessment TerminologyA change in a health or functional measure that is relevant to a patient's abilities, symptoms, or daily life. In DMD trials, a statistically significant result is not automatically clinically meaningful; the size, duration, and practical consequences of the change also matter.
• ClinicalTrials.govClinical Trial Data, Access, and ReportingA US-based public database that provides information about clinical studies conducted around the world. Families and researchers can use it to examine study objectives, eligibility criteria, locations, recruitment status, outcome measures, and posted results, although not every study record contains complete results.
• Clinician-Reported Outcome (ClinRO)Clinical Trial Endpoints and Statistical AnalysisAn assessment based on observations or judgments made by a trained healthcare professional. In DMD studies, clinician-reported outcomes may document physical findings or functional abilities using standardized methods, helping researchers monitor changes consistently across visits.
• Co-Primary EndpointsClinical Trial Endpoints and Statistical AnalysisTwo or more primary outcomes that must meet predefined statistical success criteria for a trial to achieve its main objective. In DMD research, co-primary endpoints may evaluate different aspects of function or treatment effect, depending on the study's design.
• Combination TherapyDMD Treatment and Therapeutic ApproachesThe use of two or more treatments together to achieve a therapeutic effect. In DMD, combination approaches may pair standard corticosteroid care with an investigational therapy, but studies must evaluate whether the combination improves outcomes and whether interactions or additional adverse effects occur.
• Complete Response Letter (CRL)Regulatory and Drug Development TerminologyA communication issued by the US FDA when an application cannot be approved in its current form. A CRL identifies deficiencies or issues that must be addressed, but its meaning depends on the specific application and should not automatically be interpreted as a permanent rejection.
• Composite EndpointClinical Trial Endpoints and Statistical AnalysisAn outcome that combines multiple individual events or measurements into one predefined measure. In clinical research, composite endpoints can capture several dimensions of treatment effect, but interpretation requires understanding each component and whether one component drives most of the overall result.
• Conditional Marketing AuthorizationRegulatory and Drug Development TerminologyA regulatory mechanism that permits marketing authorization under specified conditions when the relevant authority determines that the applicable criteria are met. Such authorizations may involve obligations to provide additional evidence, but requirements and terminology differ between jurisdictions.
• Confidence Interval (CI)Clinical Trial Endpoints and Statistical AnalysisA range of values calculated using a statistical method to express the uncertainty around an estimated effect. In DMD trials, confidence intervals help readers assess the precision of treatment estimates and determine which effect sizes remain compatible with the observed data.
• Confirmatory TrialRegulatory and Drug Development TerminologyA study intended to provide additional evidence that verifies or further characterizes a treatment's clinical benefit. In DMD, confirmatory trials may be required after certain types of authorization, particularly when earlier decisions relied on evidence that did not conclusively establish clinical benefit.
• ContractureDMD Treatment and Therapeutic ApproachesA persistent restriction in joint movement caused by shortening or tightening of muscles, tendons, or other tissues. In DMD, contractures can develop as muscle weakness and reduced mobility progress, affecting posture, comfort, transfers, and the ability to perform daily activities.
• Contracture ManagementRespiratory, Cardiac, and Musculoskeletal TerminologyInterventions intended to prevent, reduce, or manage restrictions in joint movement caused by shortened muscles, tendons, or other tissues. In DMD, management may involve individualized stretching, positioning, orthoses, and rehabilitation strategies to preserve mobility and comfort.
• Control GroupClinical Trial Design and Research TerminologyThe group of participants used as a reference when evaluating the investigational treatment. Depending on the trial design, the control group may receive a placebo, standard care, or another treatment, helping researchers estimate whether observed outcomes differ between groups.
• CorticosteroidsDMD Treatment and Therapeutic ApproachesA class of medicines used to reduce inflammation and help preserve muscle strength and function in DMD. Prednisone or prednisolone and deflazacort are commonly used examples, while treatment decisions require consideration of potential benefits, adverse effects, monitoring, and individual clinical circumstances.
• Creatine Kinase (CK)Biomarkers and Laboratory MeasurementsAn enzyme found in muscle cells that enters the bloodstream when muscle fibers are damaged. CK levels are often substantially elevated in DMD and may help characterize muscle injury, but changes in CK alone cannot establish whether a treatment improves muscle strength or function.
• Creatine Kinase ReductionBiomarkers and Laboratory MeasurementsA decrease in blood creatine kinase levels compared with an earlier measurement or a comparison group. Although this may suggest reduced muscle membrane leakage or damage, CK can vary for several reasons and should not be interpreted alone as proof of clinical benefit.
• Creatine Kinase Test (Creatine Kinase Testing)Biomarkers and Laboratory MeasurementsIn Duchenne Muscular Dystrophy (DMD), a Creatine Kinase (CK) test serves as a highly sensitive initial screening tool that detects ongoing, severe muscle damage. While a high CK level does not pinpoint DMD exclusively, abnormally elevated results are the primary red flag that directs physicians to order definitive genetic testing.
• Creatine Kinase-MM (CK-MM)Biomarkers and Laboratory MeasurementsThe muscle-specific form of creatine kinase, which is released into the bloodstream when skeletal muscle tissue is damaged. Measuring CK-MM can provide information about muscle injury, although levels are influenced by physical activity, disease stage, and other biological factors.
• CRISPR-Cas9DMD Genetics and Molecular BiologyA gene-editing system that uses a guide RNA and the Cas9 enzyme to target specific DNA sequences. Researchers are investigating whether CRISPR-based approaches can correct or remove disease-causing sections of the DMD gene, but safety, delivery, and long-term effectiveness remain important challenges.
• Cytokine Release Syndrome (CRS)Safety and Adverse Event TerminologyA potentially serious inflammatory reaction caused by the release of immune signaling molecules into the bloodstream. It is a recognized risk with certain immune-based treatments; whether and how it is relevant to a particular DMD intervention depends on that treatment's mechanism and observed safety data.

D

• Data Cutoff DateClinical Trial Endpoints and Statistical AnalysisThe date after which newly collected information is not included in a particular analysis. In DMD trial announcements, the cutoff date helps readers understand how much follow-up is represented and whether later safety or efficacy information may not yet be included.
• Data IntegrityClinical Trial Data, Access, and ReportingThe completeness, consistency, accuracy, and reliability of information collected and reported during research. In DMD trials, data integrity is essential for interpreting biomarker measurements, functional outcomes, adverse events, and statistical analyses without misleading omissions or inconsistencies.
• Data MonitoringClinical Trial Data, Access, and ReportingThe systematic review of information collected during a clinical study to evaluate participant safety, data quality, and protocol compliance. In DMD trials, monitoring helps identify missing information, inconsistencies, potential safety signals, and issues that may affect the reliability of reported results.
• Data SharingClinical Trial Data, Access, and ReportingThe practice of making research data available to other qualified researchers under defined conditions. In DMD, sharing appropriately protected clinical trial data may enable independent analyses, improve understanding of treatment responses, and support further research while respecting participant privacy and consent.
• Data TransparencyClinical Trial Endpoints and Statistical AnalysisThe clear and accessible reporting of study methods, results, limitations, and relevant supporting data. In DMD research, transparent reporting of functional outcomes, biomarkers, adverse events, and statistical analyses helps families and independent researchers assess the evidence behind treatment claims.
• DeflazacortDMD Treatment and Therapeutic ApproachesA corticosteroid used to treat DMD and help preserve muscle strength and function. Although it may offer clinical benefits, potential adverse effects include weight changes, reduced bone health, cataracts, growth suppression, and adrenal suppression, requiring ongoing clinical monitoring.
• Deletion MutationDuchenne Muscular Dystrophy: Disease TerminologyA genetic change in which a section of DNA is missing. Deletions in the DMD gene may remove one or more exons and disrupt dystrophin production. The exact deletion is important when assessing eligibility for certain exon-skipping therapies.
• Disease ProgressionDuchenne Muscular Dystrophy: Disease TerminologyThe gradual worsening of symptoms and functional abilities as Duchenne muscular dystrophy advances. Researchers assess progression through changes in walking ability, motor scores, muscle strength, respiratory function, cardiac measurements, and other indicators over time.
• Disease-Modifying TherapyDMD Treatment and Therapeutic ApproachesA treatment intended to alter the underlying disease process rather than only relieve symptoms. In DMD, disease-modifying approaches may target dystrophin production, genetic mutations, muscle degeneration, inflammation, or regeneration, but their benefits must be established through appropriate clinical evidence.
• DMD GeneDuchenne Muscular Dystrophy: Disease TerminologyThe gene that provides instructions for producing dystrophin, a protein essential for maintaining muscle-fiber stability. It is located on the X chromosome and contains 79 exons, with mutations capable of disrupting dystrophin production and causing Duchenne muscular dystrophy.
• Dose EscalationClinical Trial Design and Research TerminologyA study approach in which successive groups or participants receive increasing doses according to a predefined protocol. In DMD research, dose escalation can help investigators identify an appropriate dose range while monitoring safety, tolerability, and biological activity.
• Dose InterruptionSafety and Adverse Event TerminologyA temporary pause in administering an investigational treatment, often because of a safety concern, illness, or protocol-defined requirement. In DMD trials, interruptions may affect treatment exposure and must be documented to support accurate interpretation of efficacy, pharmacokinetics, and safety.
• Dose ReductionSafety and Adverse Event TerminologyA decrease in the amount of treatment administered, usually according to predefined rules or clinical judgment. In DMD research, dose reductions may be required to manage tolerability or safety concerns, and their frequency can help characterize the practical demands of a treatment regimen.
• Dose-Limiting Toxicity (DLT)Clinical Trial Design and Research TerminologyA treatment-related adverse effect severe enough, under a study's predefined rules, to limit further dose escalation. In early DMD trials, DLT criteria help investigators assess whether a dose is tolerable and determine how safely higher exposure can be explored.
• Dose-Response RelationshipClinical Trial Design and Research TerminologyThe relationship between the amount of treatment administered and the resulting biological effect, clinical outcome, or adverse event. DMD researchers may examine dose-response patterns to determine whether increasing a treatment dose produces greater activity or additional safety risks.
• Double-Blind StudyClinical Trial Design and Research TerminologyA clinical study in which participants and specified study personnel do not know which treatment assignment has been given, according to the protocol. Blinding helps reduce bias in reporting and outcome assessment, particularly when evaluating functional measures or subjective symptoms.
• Drug RepurposingDMD Treatment and Therapeutic ApproachesThe investigation of an existing medicine for a new disease or clinical indication. In DMD, repurposing may help researchers explore treatments with established human safety information, but evidence from another condition does not automatically establish effectiveness or an appropriate dose in DMD.
• Duchenne Muscular Dystrophy (DMD)Duchenne Muscular Dystrophy: Disease TerminologyA genetic disorder caused by mutations in the DMD gene that prevent the body from producing sufficient functional dystrophin. This leads to progressive muscle weakness, loss of motor function, and complications affecting the heart and respiratory muscles.
• Duplication MutationDuchenne Muscular Dystrophy: Disease TerminologyA genetic change in which a section of DNA within the DMD gene is copied one or more times. DMD gene duplications can disrupt the reading frame or interfere with dystrophin production, and their effects depend on the location and structure of the duplicated region.
• Durability of Dystrophin ExpressionAdvanced Clinical Research and Emerging Treatment ConceptsThe length of time that treatment-associated dystrophin production remains detectable or persists at a measured level. In DMD gene therapy research, repeated measurements and sufficient follow-up are needed to determine whether expression is sustained and whether it corresponds with lasting clinical benefits.
• Durability of ResponseClinical Trial Data, Access, and ReportingThe length of time a treatment's observed biological or clinical effects persist. In DMD research, durability may refer to sustained dystrophin expression, continued functional benefit, or maintained disease control, and it requires sufficient follow-up to establish how effects change over time.
• DystrophinDuchenne Muscular Dystrophy: Disease TerminologyA protein that helps stabilize muscle fibers during contraction by connecting the internal muscle structure with a supporting protein complex at the cell membrane. In DMD, insufficient functional dystrophin makes muscle fibers vulnerable to damage and progressive degeneration.
• Dystrophin ExpressionDMD Genetics and Molecular BiologyThe process through which cells produce dystrophin from genetic instructions. In DMD clinical trials, dystrophin expression may be measured to determine whether a treatment increases protein production, but the amount detected does not automatically establish meaningful improvements in muscle function.
• Dystrophin LevelBiomarkers and Laboratory MeasurementsThe measured amount of dystrophin protein in a biological sample, often expressed relative to a normal reference level. In DMD trials, this measurement can indicate whether a treatment produces the intended biological effect, but its clinical meaning depends on protein quality and functional outcomes.
• Dystrophin QuantificationDMD Genetics and Molecular BiologyThe laboratory measurement of how much dystrophin is present in a biological sample, usually muscle tissue. Researchers may use Western blot or immunohistochemistry to evaluate protein abundance or distribution, but results depend on the method, sample quality, and analysis procedures.
• Dystrophin RestorationDMD Genetics and Molecular BiologyAn increase in dystrophin production or the recovery of some dystrophin-related function following treatment. Researchers assess restoration using laboratory methods and muscle biopsies, but its clinical significance depends on the amount, distribution, quality, and functional activity of the protein.
• Dystrophin-Associated Protein Complex (DAPC)Duchenne Muscular Dystrophy: Disease TerminologyA group of proteins located at the muscle-cell membrane that helps connect the internal structural framework of a muscle fiber to its surrounding environment. Dystrophin is a key component of this complex, which supports muscle stability during repeated contractions.
• Dystrophin-Positive FibersBiomarkers and Laboratory MeasurementsMuscle fibers in which dystrophin is detectable using a specified laboratory staining method. Researchers may report the percentage of positive fibers after treatment, but this does not directly show how much functional dystrophin each fiber produces or whether overall muscle performance improves.
• DystrophinopathyDuchenne Muscular Dystrophy: Disease TerminologyAn umbrella term for genetic disorders caused by mutations in the DMD gene, including Duchenne muscular dystrophy, Becker muscular dystrophy, and certain heart conditions. The clinical presentation depends partly on how the mutation affects dystrophin production and function.

E

• EchocardiogramSafety and Adverse Event TerminologyAn ultrasound examination used to assess the structure and function of the heart. In DMD, echocardiography may measure ventricular function and detect signs of cardiomyopathy, supporting cardiac monitoring during routine care and clinical trials.
• Effect SizeClinical Trial Endpoints and Statistical AnalysisA numerical estimate describing the magnitude of a difference or relationship observed in a study. In DMD clinical trials, effect size helps researchers understand how large a treatment-associated change is, complementing statistical significance and supporting assessment of its potential clinical relevance.
• EffectivenessClinical Trial Endpoints and Statistical AnalysisThe extent to which a treatment provides benefits in routine clinical practice outside the controlled conditions of a trial. In DMD, real-world effectiveness may differ from trial efficacy because of patient characteristics, treatment adherence, access to care, and differences in monitoring.
• EfficacyClinical Trial Endpoints and Statistical AnalysisThe extent to which a treatment produces its intended effect under the conditions of a clinical study. In DMD trials, efficacy is evaluated through predefined endpoints and appropriate statistical comparisons, rather than relying solely on biological activity or isolated positive findings.
• Electrocardiogram (ECG)Safety and Adverse Event TerminologyA test that records the electrical activity of the heart. In DMD studies, electrocardiograms can help identify cardiac rhythm or conduction abnormalities and contribute to safety monitoring, although additional cardiac investigations may be required to assess heart-muscle structure and function.
• Eligibility CriteriaClinical Trial Design and Research TerminologyThe complete set of inclusion and exclusion requirements used to determine whether a person can enter a clinical trial. In DMD research, eligibility rules may restrict participation by age, mutation, disease stage, previous treatment, or other clinical characteristics.
• EndpointClinical Trial Endpoints and Statistical AnalysisA predefined outcome measured in a clinical trial to evaluate a treatment's effects. DMD endpoints may assess motor function, dystrophin production, safety, respiratory capacity, or other outcomes, and their interpretation depends on the study design and the question being investigated.
• Endpoint HierarchyClinical Trial Endpoints and Statistical AnalysisThe predefined ordering and statistical relationship among primary, secondary, and other trial outcomes. A clear hierarchy helps researchers interpret which findings support the main study objective and which results are supplementary or exploratory, reducing the risk of overinterpreting multiple comparisons.
• EnrollmentClinical Trial Design and Research TerminologyThe formal entry of an eligible participant into a clinical study according to its protocol. Enrollment usually follows screening and informed consent, although public recruitment announcements may use the term more broadly when describing the number of participants accepted into a trial.
• European Medicines Agency (EMA)Regulatory and Drug Development TerminologyThe European Union agency that coordinates scientific evaluation and monitoring of medicines within its remit. For DMD therapies, the EMA plays a central role in evaluating many medicines through the EU centralized procedure, while formal authorization decisions are made under the applicable EU process.
• Evidence-Based MedicineAdvanced Clinical Research and Emerging Treatment ConceptsThe integration of the best available research evidence with clinical expertise and patient preferences when making healthcare decisions. In DMD, evidence-based practice involves critically evaluating clinical trials, safety findings, functional outcomes, biomarkers, and the applicability of results to individual patients.
• Exclusion CriteriaClinical Trial Design and Research TerminologyThe predefined conditions or characteristics that prevent someone from participating in a clinical study. In DMD trials, these criteria may relate to medical risks, previous treatments, laboratory findings, genetic characteristics, or other factors that could affect participant safety or result interpretation.
• ExonDuchenne Muscular Dystrophy: Disease TerminologyA segment of a gene that remains in the mature messenger RNA after RNA processing. The DMD gene contains 79 exons, and mutations affecting these regions can disrupt dystrophin production. Exon identification is essential for determining eligibility for exon-skipping treatments.
• Exon 45 SkippingDMD Treatment and Therapeutic ApproachesA mutation-specific approach intended to skip exon 45 during dystrophin RNA processing. For eligible genetic variants, this may help restore the reading frame and permit production of a shorter dystrophin protein, but treatment suitability depends on the precise mutation and the therapy's approved indication.
• Exon 51 SkippingDMD Treatment and Therapeutic ApproachesA mutation-specific treatment strategy designed to exclude exon 51 from dystrophin messenger RNA during processing. It may restore the reading frame for certain DMD mutations and enable production of a shorter dystrophin protein, although the amount produced and resulting clinical benefit can vary.
• Exon 53 SkippingDMD Treatment and Therapeutic ApproachesA treatment strategy that targets exon 53 during dystrophin RNA processing to restore the reading frame in certain DMD mutations. Eligibility depends on the exact genetic variant, and the presence of an exon 53 deletion alone does not automatically establish suitability for every exon-skipping approach.
• Exon SkippingDuchenne Muscular Dystrophy: Disease TerminologyA treatment strategy that uses specific molecules to encourage cells to skip a targeted exon during RNA processing. This can restore the reading frame in certain DMD mutations and allow production of a shorter dystrophin protein, although the amount and function of the protein may vary.
• Exploratory EndpointClinical Trial Endpoints and Statistical AnalysisAn outcome investigated to generate evidence or identify potential treatment effects that may require further study. In DMD trials, exploratory endpoints can include emerging biomarkers, imaging measurements, or molecular indicators that are not established as definitive measures of clinical benefit.
• Exposure-Response RelationshipBiomarkers and Laboratory MeasurementsThe relationship between the amount of treatment reaching the body and the resulting biological, clinical, or safety effects. In DMD trials, researchers may examine whether higher drug exposure produces greater target engagement or clinical benefit, while also evaluating the possibility of increased adverse effects.
• External Control ArmClinical Trial Endpoints and Statistical AnalysisA comparison group drawn from data outside the current randomized trial, such as an earlier clinical study or patient registry. In DMD research, external controls can provide useful context, but differences in eligibility, assessments, treatment history, and follow-up can introduce bias.

F

• Fast Track DesignationRegulatory and Drug Development TerminologyA US regulatory designation intended to facilitate the development and review of treatments for serious conditions that address unmet medical needs. A DMD treatment receiving Fast Track designation may qualify for certain interactions or review mechanisms, but designation does not guarantee approval.
• Fat FractionBiomarkers and Laboratory MeasurementsThe proportion of tissue volume attributable to fat, often measured using specialized MRI techniques. In DMD, increasing muscle fat fraction can reflect progressive replacement of muscle tissue, while longitudinal measurements may help researchers investigate whether a treatment slows structural deterioration.
• FatigueRespiratory, Cardiac, and Musculoskeletal TerminologyA subjective or measurable reduction in physical or mental capacity that may affect daily activities. In DMD, fatigue can be influenced by muscle weakness, physical exertion, sleep-related breathing problems, medication effects, and other factors, so its causes require careful assessment.
• Fatty ReplacementDMD Genetics and Molecular BiologyThe replacement of damaged muscle tissue with fat as the disease progresses. In DMD, magnetic resonance imaging can detect changes in muscle composition, helping researchers evaluate disease severity and investigate whether a treatment may slow structural deterioration.
• FDARegulatory and Drug Development TerminologyThe US Food and Drug Administration, the federal agency responsible for regulating a range of medical products, including drugs and biological therapies. In DMD, the FDA evaluates treatment applications under US law and may authorize products for specific indications when applicable requirements are met.
• FibrosisDMD Genetics and Molecular BiologyThe excessive accumulation of connective tissue within an organ or muscle. In DMD, chronic muscle injury and inflammation can promote fibrosis, which replaces functional muscle tissue and may contribute to reduced flexibility, impaired movement, and declining muscle performance.
• First-in-Human StudyAdvanced Clinical Research and Emerging Treatment ConceptsAn early clinical study in which a treatment is administered to humans for the first time. In DMD development, such studies typically emphasize safety, tolerability, dosing, and initial biological activity, with careful monitoring because human exposure may be limited or entirely new.
• Follow-Up PeriodClinical Trial Design and Research TerminologyThe period during which participants are monitored after a treatment or study assessment. In DMD trials, follow-up can reveal whether changes in biomarkers or function persist and help identify delayed adverse events, loss of treatment effect, or longer-term safety concerns.
• Forced Expiratory Volume in One Second (FEV1)Respiratory, Cardiac, and Musculoskeletal TerminologyThe volume of air a person can forcibly exhale during the first second of a spirometry test after taking a full breath. In DMD, FEV1 may help characterize respiratory function, although interpretation should consider other measurements and the pattern of muscle weakness.
• Forced Vital Capacity (FVC)Safety and Adverse Event TerminologyThe maximum volume of air a person can forcibly exhale after taking a full breath, measured using spirometry. In DMD, FVC is commonly used to monitor respiratory muscle weakness and may help researchers evaluate the progression of respiratory impairment over time.
• Frameshift MutationDuchenne Muscular Dystrophy: Disease TerminologyA genetic alteration that changes how DNA is read in groups of three nucleotides during protein production. In DMD, frameshift mutations often disrupt the dystrophin reading frame, leading to premature termination and little or no functional dystrophin.
• Full-Length DystrophinDMD Genetics and Molecular BiologyThe complete form of the dystrophin protein normally produced from the DMD gene. Because the gene is exceptionally large, delivering its entire coding sequence using conventional viral gene therapy vectors presents major technical challenges for researchers developing DMD treatments.
• Functional EndpointNSAA and Functional Assessment TerminologyA clinical trial outcome based on the ability to perform a physical activity or everyday task. DMD functional endpoints include NSAA scores, walking distance, timed tests, and upper-limb assessments, which help determine whether a treatment changes measured physical abilities.
• Functional ProteinAdvanced Clinical Research and Emerging Treatment ConceptsA protein that retains the biological activity required for its normal role, wholly or partly. In DMD research, the presence of a shortened dystrophin protein does not automatically establish how effectively it supports muscle fibers, so protein structure and functional outcomes are important considerations.

G

• Gene EditingDMD Genetics and Molecular BiologyA group of technologies designed to make targeted changes to DNA within cells. In DMD research, gene editing may aim to correct a mutation, remove selected genetic segments, or restore the dystrophin reading frame, depending on the specific strategy and mutation involved.
• Gene Replacement TherapyDMD Treatment and Therapeutic ApproachesA treatment approach that introduces genetic instructions intended to provide a functional version or portion of a missing protein. In DMD, gene replacement programs often use engineered microdystrophin because conventional delivery systems cannot easily accommodate the full-length DMD coding sequence.
• Gene TherapyDMD Genetics and Molecular BiologyA treatment approach that delivers genetic material into cells to produce a therapeutic effect. In DMD, gene therapy may deliver instructions for an engineered dystrophin protein, but treatment outcomes depend on delivery efficiency, immune responses, protein expression, and long-term safety.
• GeneralizabilityClinical Trial Data, Access, and ReportingThe extent to which study findings can reasonably apply to people beyond the participants who were studied. In DMD, results from a narrowly defined trial population may not automatically apply to younger children, non-ambulatory individuals, different mutations, or patients with other clinical characteristics.
• GenotypeDuchenne Muscular Dystrophy: Disease TerminologyThe specific genetic makeup of an individual, including the type and location of a mutation in the DMD gene. A person's genotype helps establish a DMD diagnosis and determine whether mutation-specific treatments, such as certain exon-skipping therapies, may be appropriate.
• Genotype-Phenotype CorrelationDuchenne Muscular Dystrophy: Disease TerminologyThe relationship between a genetic mutation and the characteristics of the resulting disease. In DMD, this relationship can help explain differences in dystrophin production, symptom severity, disease progression, and potential eligibility for mutation-specific treatments.
• Geographic AccessClinical Trial Data, Access, and ReportingThe ability of patients to reach clinical research opportunities or obtain approved treatments within their region or country. In DMD, geographic access may be affected by trial-site distribution, eligibility restrictions, travel requirements, healthcare infrastructure, and regulatory or reimbursement policies.
• Gross Motor FunctionNSAA and Functional Assessment TerminologyThe ability to perform movements involving large muscle groups, such as walking, running, jumping, and maintaining balance. Gross motor assessments are particularly relevant in ambulatory DMD participants because progressive weakness can gradually limit these activities.

H

• Health-Related Quality of Life (HRQoL)Clinical Trial Data, Access, and ReportingA measure of how a person's health affects physical, emotional, and social well-being. In DMD research, quality-of-life assessments can complement motor and laboratory outcomes by examining daily functioning, participation, symptoms, and the broader effects of treatment.
• HepatotoxicitySafety and Adverse Event TerminologyThe capacity of a substance or treatment to cause liver injury. In DMD clinical trials, researchers monitor relevant laboratory tests and clinical signs to identify potential hepatotoxic effects, while distinguishing liver abnormalities from enzyme elevations caused by underlying muscle disease.
• HydrotherapyDMD Treatment and Therapeutic ApproachesA therapeutic approach that uses water-based activities or exercises to support movement, comfort, and physical participation. In DMD, hydrotherapy may help individuals exercise with reduced weight-bearing demands, but activities should be adapted to individual abilities and clinical recommendations.

I

• ImmunofluorescenceDMD Genetics and Molecular BiologyA laboratory technique that uses fluorescently labelled antibodies to visualize specific proteins in cells or tissues. In DMD studies, it can help researchers examine dystrophin localization and the proportion of muscle fibers showing detectable protein staining after treatment.
• ImmunogenicitySafety and Adverse Event TerminologyThe ability of a treatment or therapeutic product to trigger an immune response. In DMD gene therapy trials, immunogenicity may involve antibodies or cellular responses directed against a viral vector or therapeutic protein, potentially affecting safety, treatment activity, or eligibility for future dosing.
• Immunohistochemistry (IHC)DMD Genetics and Molecular BiologyA laboratory method that uses antibodies to detect specific proteins in tissue sections. In DMD research, immunohistochemistry can show where dystrophin is located along muscle-fiber membranes and help assess protein distribution following an investigational treatment.
• In-Frame MutationDuchenne Muscular Dystrophy: Disease TerminologyA genetic alteration that preserves the reading frame of the genetic code, allowing the production of a shortened dystrophin protein. In-frame mutations are often associated with Becker muscular dystrophy, although the resulting protein's function and clinical severity can vary.
• Inclusion CriteriaClinical Trial Design and Research TerminologyThe predefined characteristics that a person must meet to participate in a clinical trial. DMD inclusion criteria may specify age, genetic confirmation, ambulatory status, mutation type, steroid use, or other health requirements relevant to the treatment being investigated.
• Independent Data ReviewAdvanced Clinical Research and Emerging Treatment ConceptsAn evaluation of research findings by individuals or organizations independent of the study sponsor. In DMD research, independent review can help assess whether reported results support the stated conclusions, identify limitations, and improve confidence in the interpretation of clinical and laboratory data.
• Independent Safety Monitoring CommitteeSafety and Adverse Event TerminologyA group of qualified experts that reviews accumulating clinical trial safety data, and sometimes other data, according to its charter. Depending on the study, the committee may recommend continuing, modifying, pausing, or stopping a trial to protect participants.
• Individual Participant Data (IPD)Clinical Trial Data, Access, and ReportingDetailed information collected about each participant in a clinical study, rather than only group-level summaries. In DMD research, IPD may support analyses of age, genotype, baseline function, biomarker changes, and treatment response, subject to privacy protections and applicable data-sharing rules.
• Informed ConsentClinical Trial Design and Research TerminologyA documented process in which a potential participant or legally authorized representative receives and understands relevant information before agreeing to take part in research. It includes discussion of study procedures, potential benefits, risks, alternatives, and the right to withdraw.
• Intention-to-Treat (ITT) AnalysisClinical Trial Endpoints and Statistical AnalysisAn analysis approach that generally evaluates participants according to their originally assigned study groups, regardless of whether they fully followed the treatment plan. When appropriately implemented, ITT helps preserve the benefits of randomization and reduces certain forms of bias.
• Interim AnalysisClinical Trial Endpoints and Statistical AnalysisAn analysis of trial data conducted before the planned study completion. In DMD trials, interim analyses may assess safety, treatment activity, or predefined stopping criteria, but early results can be uncertain and may not reflect the final treatment effect.
• IntronDuchenne Muscular Dystrophy: Disease TerminologyA non-coding region within a gene that is removed from the initial RNA transcript during RNA splicing. Although introns do not usually encode the protein sequence directly, changes in intronic regions can interfere with normal RNA processing and cause DMD.
• Investigational Medicinal Product (IMP)Regulatory and Drug Development TerminologyA medicinal product being tested or used as a reference in a clinical trial under the applicable regulatory framework. In DMD studies, an IMP may be an experimental therapy, placebo, or comparator, depending on the trial design and relevant rules.
• Investigational New Drug (IND)Regulatory and Drug Development TerminologyA regulatory status associated with a drug being studied in humans under applicable US requirements before it is legally marketed for that use. An IND supports authorized clinical investigation; it does not mean that the treatment is approved or proven effective for DMD.
• Investigational TreatmentAdvanced Clinical Research and Emerging Treatment ConceptsA medicine, biological product, or other intervention being evaluated for a use that has not yet been established through the applicable regulatory process. In DMD, investigational treatments may show promising early findings, but their safety and effectiveness remain under evaluation until sufficient evidence is available.

L

• Laboratory Reference RangeBiomarkers and Laboratory MeasurementsThe range of values considered typical for a particular laboratory test in a defined reference population. DMD patients may have results well outside standard ranges, and interpretation should account for disease-related changes, age, testing methods, and the clinical question being investigated.
• Lactate Dehydrogenase (LDH)Biomarkers and Laboratory MeasurementsAn enzyme involved in cellular energy metabolism that is present in muscle and many other tissues. Blood LDH levels may increase in DMD because of muscle damage, but the measurement is nonspecific and cannot independently determine disease severity or treatment effectiveness.
• Left Ventricular Ejection Fraction (LVEF)Safety and Adverse Event TerminologyThe percentage of blood in the left ventricle pumped out with each heartbeat. LVEF is one measure of cardiac function and may be monitored in DMD, although it can remain within a typical range despite early cardiac abnormalities and should not be interpreted alone.
• Lipid Nanoparticle (LNP)DMD Treatment and Therapeutic ApproachesA small particle made from lipid components that can package and deliver biological molecules into cells. Lipid nanoparticles are widely investigated for nucleic-acid delivery, and researchers may explore their potential for DMD-related genetic approaches, although muscle targeting remains a major challenge.
• Liver ToxicitySafety and Adverse Event TerminologyTreatment-associated or disease-associated injury affecting the liver, assessed through clinical findings, laboratory tests, and other investigations. In DMD, interpretation can be complicated because AST and ALT may originate from skeletal muscle, so additional evidence is needed to establish liver-specific injury.
• Local Gene DeliveryDMD Treatment and Therapeutic ApproachesThe administration of genetic material directly into a specific tissue or anatomical region. In DMD research, local delivery can help investigate biological activity within a targeted area, but findings from a limited region may not reflect treatment distribution or effectiveness throughout the body.
• Long-Term Follow-Up (LTFU)Clinical Trial Data, Access, and ReportingMonitoring conducted over an extended period after or during treatment to evaluate durability, delayed adverse events, and longer-term outcomes. In DMD gene therapy research, long-term follow-up can be particularly important because some risks and effects may not be fully apparent during short trials.
• Longitudinal Biomarker AssessmentBiomarkers and Laboratory MeasurementsThe repeated measurement of a biological indicator at multiple time points. In DMD studies, longitudinal assessments can help researchers examine whether changes in CK, dystrophin, or muscle imaging persist over time and whether they correspond with changes in clinical outcomes.
• Loss of Ambulation (LoA)Duchenne Muscular Dystrophy: Disease TerminologyThe loss of the ability to walk independently, representing an important milestone in Duchenne muscular dystrophy. Clinical studies may measure the age at which this occurs or assess whether a treatment delays its onset compared with the expected disease progression.
• Loss of Motor FunctionNSAA and Functional Assessment TerminologyThe reduction or disappearance of an ability that a participant previously performed. In DMD, clinical studies may track the loss of specific tasks or broader functional abilities to assess disease progression and determine whether a treatment helps preserve independence.

M

• Marketing AuthorizationRegulatory and Drug Development TerminologyFormal permission from a regulatory authority to market a medicinal product for defined indications under specified conditions. For DMD treatments, the authorization identifies the approved population and use, and it may include requirements for additional studies or ongoing safety monitoring.
• Maximum Tolerated Dose (MTD)Clinical Trial Design and Research TerminologyThe highest dose of a treatment that can be administered under a study's specified conditions without unacceptable toxicity. Not every DMD treatment program seeks to establish an MTD, because the optimal dose may instead be determined by biological activity, efficacy, and overall safety.
• Mechanism of Action (MoA)Advanced Clinical Research and Emerging Treatment ConceptsThe biological process through which a treatment produces its intended effects. In DMD, a treatment's mechanism of action may involve altering RNA processing, delivering genetic instructions, modifying inflammatory pathways, or supporting muscle regeneration, depending on the therapeutic approach.
• Messenger RNA (mRNA)Duchenne Muscular Dystrophy: Disease TerminologyA molecule that carries genetic instructions from DNA to the cellular machinery responsible for producing proteins. In DMD, researchers study dystrophin mRNA to assess how genetic mutations or exon-skipping treatments affect the instructions used to produce dystrophin.
• MicrodystrophinDMD Genetics and Molecular BiologyA shortened, engineered version of dystrophin designed to fit within the delivery capacity of certain viral gene therapy vectors. Microdystrophin therapies aim to provide some muscle-protective function, but the engineered protein lacks portions of the full-length dystrophin structure.
• Microdystrophin Gene TherapyDMD Treatment and Therapeutic ApproachesA form of gene therapy designed to deliver instructions for a shortened dystrophin protein into muscle cells. In DMD, researchers evaluate whether the treatment produces microdystrophin, how widely it reaches muscle tissue, and whether biological changes translate into meaningful clinical benefits.
• Minimal Clinically Important Difference (MCID)NSAA and Functional Assessment TerminologyThe smallest change in an assessment score that is considered meaningful from the patient's or clinician's perspective. For DMD outcome measures, the MCID helps distinguish changes that may matter in daily life from numerical differences that may have limited practical significance.
• Missing DataClinical Trial Endpoints and Statistical AnalysisInformation that was not collected or is unavailable for a planned study assessment. In DMD trials, missing data may arise from missed visits, withdrawal, illness, or inability to complete a test, and the reasons and statistical handling can influence the interpretation of results.
• Morpholino OligomerDMD Treatment and Therapeutic ApproachesA synthetic antisense molecule with a modified backbone designed to bind complementary RNA sequences. Certain morpholino-based treatments are used in DMD exon-skipping research to alter dystrophin RNA processing, although their effects depend on the targeted exon, delivery, and individual mutation.
• Motor FunctionNSAA and Functional Assessment TerminologyThe ability to control muscles and perform movements, including standing, walking, climbing stairs, and using the arms. In DMD studies, motor function is evaluated through standardized scales and timed tasks to monitor disease progression and assess potential treatment benefits.
• Motor MilestoneNSAA and Functional Assessment TerminologyA functional ability that can be identified as a meaningful stage in motor development or decline. In DMD, examples include rising from the floor, climbing stairs, and losing independent walking ability, and studies may measure when these milestones occur.
• Multicenter TrialClinical Trial Design and Research TerminologyA clinical study conducted at multiple research sites under a shared protocol. In DMD, multicenter trials can recruit participants more efficiently and include a wider range of patients, while requiring consistent training, assessment methods, and data collection across locations.
• MultiplicityClinical Trial Endpoints and Statistical AnalysisThe statistical problem that arises when multiple hypotheses, endpoints, or comparisons are tested. In DMD trials, testing many outcomes without appropriate adjustment can increase the probability of false-positive findings, making prespecified statistical plans and transparent reporting important.
• Muscle BiopsyDMD Genetics and Molecular BiologyA medical procedure in which a small sample of muscle tissue is collected for laboratory analysis. DMD clinical trials may use biopsies to examine dystrophin production, muscle pathology, or treatment-related changes, although the procedure is invasive and samples represent only a limited tissue area.
• Muscle FiberDuchenne Muscular Dystrophy: Disease TerminologyA specialized muscle cell that contracts to generate movement. In DMD, muscle fibers are repeatedly damaged because they lack sufficient functional dystrophin, leading to inflammation, degeneration, and replacement of healthy muscle tissue with fat and connective tissue.
• Muscle Magnetic Resonance Imaging (Muscle MRI)Biomarkers and Laboratory MeasurementsAn imaging technique that examines muscle structure and composition without requiring surgery. DMD studies may use MRI to assess muscle volume, fat replacement, and tissue changes, providing information about disease progression or treatment effects beyond functional tests alone.
• Muscle RegenerationDMD Genetics and Molecular BiologyThe process by which damaged muscle tissue repairs itself through the activation and differentiation of muscle precursor cells. In DMD, ongoing degeneration can exceed the body's regenerative capacity, prompting research into treatments that may improve muscle repair and preserve functional tissue.
• Muscle Regeneration TherapyDMD Treatment and Therapeutic ApproachesAn approach designed to support the repair, growth, or replacement of damaged muscle tissue. In DMD research, regenerative therapies may target muscle stem cells, cellular signaling, or other biological pathways, with the goal of preserving functional tissue or improving muscle repair.
• Mutation-Agnostic TherapyAdvanced Clinical Research and Emerging Treatment ConceptsA treatment approach intended to work across different DMD gene mutations rather than requiring one specific genetic variant. Examples under investigation include strategies targeting muscle regeneration or other shared disease processes, although effectiveness must be demonstrated for the intended patient population.
• Mutation-Specific TherapyAdvanced Clinical Research and Emerging Treatment ConceptsA treatment designed for individuals whose genetic variants meet defined molecular eligibility requirements. In DMD, exon-skipping treatments are examples of mutation-specific approaches, and determining eligibility requires accurate genetic characterization rather than diagnosis alone.
• Myocardial FibrosisRespiratory, Cardiac, and Musculoskeletal TerminologyThe accumulation of scar-like connective tissue within the heart muscle. In DMD, myocardial fibrosis can develop as dystrophin deficiency damages cardiac tissue and may precede significant impairment in pumping function, making it an important finding in cardiac assessment.
• MyofiberDMD Genetics and Molecular BiologyAn individual muscle fiber, or muscle cell, that contributes to skeletal muscle contraction. In DMD studies, researchers may examine myofiber size, structural damage, and dystrophin staining to understand muscle pathology and assess biological responses to investigational therapies.
• MyogenesisDMD Genetics and Molecular BiologyThe biological process through which muscle cells develop, differentiate, and form muscle fibers. Researchers studying DMD investigate myogenesis and muscle regeneration to understand how treatments might improve muscle repair, maintain muscle tissue, or address limitations of approaches focused primarily on dystrophin replacement.
• Myostatin InhibitionDMD Treatment and Therapeutic ApproachesA therapeutic strategy intended to reduce the activity of myostatin, a protein that normally limits skeletal muscle growth. Researchers have investigated myostatin inhibition in DMD to determine whether increasing muscle mass can improve function, but larger muscles do not necessarily produce greater strength or mobility.

N

• Natural HistoryDuchenne Muscular Dystrophy: Disease TerminologyThe typical progression of a disease over time without the effects of the treatment being investigated. DMD natural history studies help researchers understand expected changes in motor function, muscle strength, respiratory capacity, and other outcomes across different ages and disease stages.
• Natural History ComparatorClinical Trial Endpoints and Statistical AnalysisA reference group or dataset describing disease progression in participants who are not receiving the investigational treatment under evaluation. DMD studies may use natural history data when a concurrent control group is difficult to establish, but differences between datasets can complicate comparisons.
• Neutralizing Antibodies (NAbs)Safety and Adverse Event TerminologyAntibodies that can reduce or block the biological activity of a therapeutic agent or its delivery system. In AAV-based DMD gene therapy, pre-existing neutralizing antibodies may interfere with vector delivery and can influence eligibility, while treatment-induced responses may complicate future administration.
• New Drug Application (NDA)Regulatory and Drug Development TerminologyAn application submitted to the US FDA seeking approval to market a drug under the applicable regulatory framework. An NDA generally contains evidence and documentation about clinical studies, manufacturing, safety, effectiveness, labeling, and other requirements relevant to the proposed indication.
• Nocturnal HypoventilationRespiratory, Cardiac, and Musculoskeletal TerminologyInadequate ventilation during sleep that leads to insufficient removal of carbon dioxide and, in some cases, reduced oxygen levels. In DMD, respiratory muscle weakness may cause nocturnal hypoventilation before major daytime breathing difficulties become apparent.
• Non-AmbulatoryDuchenne Muscular Dystrophy: Disease TerminologyA term describing individuals who can no longer walk independently. In DMD, this stage may require greater emphasis on upper-limb function, transfers, respiratory health, cardiac monitoring, and maintaining independence in daily activities.
• Non-Invasive Ventilation (NIV)Respiratory, Cardiac, and Musculoskeletal TerminologyBreathing support delivered through a mask or another external interface without an invasive airway. In DMD, non-invasive ventilation may support breathing during sleep or other periods of respiratory insufficiency, according to individual clinical needs and specialist recommendations.
• Non-ResponderAdvanced Clinical Research and Emerging Treatment ConceptsA participant who does not meet a study's predefined criteria for treatment response. In DMD research, lack of response may reflect biological variability, disease stage, treatment exposure, measurement limitations, or other factors and should not be interpreted without considering the study's response definition.
• Non-Viral Gene DeliveryDMD Treatment and Therapeutic ApproachesA method of delivering genetic material into cells without using a virus-based vector. In DMD research, non-viral systems may offer alternative approaches to gene delivery, but their ability to reach muscle tissue, produce sufficient expression, and maintain acceptable safety requires careful evaluation.
• Nonsense MutationDuchenne Muscular Dystrophy: Disease TerminologyA genetic change that introduces a premature stop signal into the coding sequence of a gene. In DMD, this can interrupt dystrophin production before the protein is complete. Nonsense mutations are one potential target for specialized readthrough treatment approaches.
• North Star Ambulatory Assessment (NSAA)NSAA and Functional Assessment TerminologyA standardized assessment used to measure motor abilities in ambulatory individuals with Duchenne muscular dystrophy. It includes 17 functional tasks, such as standing, walking, jumping, and rising from the floor, and is commonly used to monitor disease progression and treatment effects.
• North Star Assessment for Limb Girdle Function (NSAD)NSAA and Functional Assessment TerminologyA functional assessment developed to evaluate motor abilities in people with limb-girdle muscular dystrophy and related conditions. It is distinct from the NSAA, which was developed specifically to assess ambulatory motor performance in DMD.
• NSAA Ceiling EffectNSAA and Functional Assessment TerminologyA measurement limitation that occurs when a participant achieves the highest available score, leaving little or no room for further improvement to be recorded. In DMD studies, ceiling effects may complicate assessments of younger or higher-functioning participants who perform nearly all tasks successfully.
• NSAA DeclineNSAA and Functional Assessment TerminologyA reduction in the NSAA total score over time, indicating a loss of measured motor abilities or worsening performance. In DMD trials, researchers examine whether treatment slows this decline compared with an appropriate control group or the expected natural history of the disease.
• NSAA Floor EffectNSAA and Functional Assessment TerminologyA measurement limitation that occurs when a participant scores at or near the lowest possible value, leaving little room to record further deterioration. This can become relevant in advanced DMD when many assessed motor tasks are no longer achievable independently.
• NSAA ImprovementNSAA and Functional Assessment TerminologyAn increase in the NSAA total score compared with an earlier assessment. Such a change may reflect improved performance or the acquisition of motor abilities, particularly in younger children, but it should be interpreted alongside age-related development, measurement variability, and other outcomes.
• NSAA Item ScoreNSAA and Functional Assessment TerminologyThe score assigned to an individual activity within the North Star Ambulatory Assessment. Under the standard scoring system, 0 means the task cannot be achieved independently, 1 indicates a modified method without physical assistance, and 2 indicates performance without obvious modification.
• NSAA PlateauNSAA and Functional Assessment TerminologyA period during which the NSAA total score remains relatively stable rather than increasing or decreasing substantially. In DMD research, maintaining motor function may be meaningful when decline would otherwise be expected, but stability must be evaluated over a defined period and against an appropriate comparator.
• NSAA Score Change from BaselineNSAA and Functional Assessment TerminologyThe difference between a participant's NSAA total score at a later assessment and the score recorded before treatment or study observation began. This change helps researchers evaluate motor-function trajectories, but results must be interpreted in relation to age, disease stage, and the comparison group.
• NSAA Total ScoreNSAA and Functional Assessment TerminologyThe sum of the scores assigned to the applicable NSAA activities. Each item is generally scored 0, 1, or 2, with a maximum of 34 when all 17 items are scored. A higher total indicates better measured motor performance, but age and disease stage affect interpretation.

O

• Observer-Reported Outcome (ObsRO)Clinical Trial Endpoints and Statistical AnalysisA measure completed by someone who observes a participant's behavior or functioning but does not interpret the information as a healthcare professional. In DMD research, an observer may report directly observed activities when the participant cannot reliably provide the information themselves.
• Open-Label StudyClinical Trial Design and Research TerminologyA clinical study in which participants and investigators know which treatment is being administered. Open-label designs can provide useful safety and long-term data, but the absence of blinding may influence expectations, reporting, and the assessment of subjective outcomes.
• Orphan Drug Designation (ODD)Regulatory and Drug Development TerminologyA regulatory designation intended to encourage the development of treatments for rare diseases. In DMD, orphan designation may provide specified development incentives, but it does not mean that a treatment has demonstrated effectiveness or received marketing approval.
• Orthotic DeviceDMD Treatment and Therapeutic ApproachesAn external device designed to support, align, protect, or improve the function of a body part. In DMD, orthoses may help manage ankle tightness, support positioning, or assist mobility, with selection depending on the individual's needs and the recommendations of the clinical team.
• OsteoporosisRespiratory, Cardiac, and Musculoskeletal TerminologyA condition characterized by reduced bone strength and increased susceptibility to fractures. People with DMD may be at increased risk because of reduced weight-bearing activity, muscle weakness, and corticosteroid treatment, requiring individualized monitoring and management of bone health.
• Out-of-Frame MutationDuchenne Muscular Dystrophy: Disease TerminologyA genetic alteration that disrupts the reading frame used to produce dystrophin. It often results in a premature stop signal and little or no functional protein, making it a common genetic mechanism underlying Duchenne muscular dystrophy.
• Outcome MeasureClinical Trial Endpoints and Statistical AnalysisA standardized method used to assess a participant's health, function, symptoms, or biological status. DMD studies use outcome measures such as NSAA, six-minute walk distance, respiratory tests, and laboratory biomarkers to evaluate disease progression and potential treatment effects.

P

• P-ValueClinical Trial Endpoints and Statistical AnalysisA statistical quantity representing the probability, under a specified null hypothesis and statistical model, of obtaining results at least as extreme as those observed. A small p-value does not indicate the probability that a treatment works or measure the size of its clinical benefit.
• Pain AssessmentRespiratory, Cardiac, and Musculoskeletal TerminologyA structured evaluation of the presence, intensity, location, duration, and impact of pain. In DMD, pain may be associated with contractures, posture, fractures, or other complications, and systematic assessment helps clinicians identify potential causes and guide management.
• Patient PopulationClinical Trial Data, Access, and ReportingThe group of individuals included in or intended for a clinical study or treatment indication. In DMD research, the population may be defined by age, mutation type, ambulatory status, previous treatment, or disease stage, all of which can influence how results should be interpreted.
• Patient-Centered OutcomeClinical Trial Data, Access, and ReportingAn outcome that reflects matters important to patients, such as daily functioning, independence, symptoms, treatment burden, or quality of life. In DMD trials, patient-centered outcomes can complement biomarkers and functional scales to provide a broader assessment of meaningful treatment effects.
• Patient-Reported Outcome (PRO)Clinical Trial Endpoints and Statistical AnalysisA measure based directly on information provided by the patient without interpretation by another person. In DMD research, patient-reported outcomes may assess symptoms, fatigue, pain, or quality of life, although age and communication abilities can affect the choice of instrument.
• Peak Cough Flow (PCF)Safety and Adverse Event TerminologyA measurement of the maximum airflow produced during a cough. In DMD, declining respiratory muscle strength can weaken cough effectiveness, so peak cough flow may help assess the ability to clear airway secretions and identify when additional respiratory support is needed.
• Peer-Reviewed PublicationClinical Trial Endpoints and Statistical AnalysisA scientific article evaluated by independent experts before publication in a scholarly journal. Peer review can improve the quality and transparency of DMD research reporting, although publication alone does not guarantee that a study is free from methodological limitations or bias.
• Per-Protocol AnalysisClinical Trial Endpoints and Statistical AnalysisAn analysis that focuses on participants who met predefined requirements for following the study protocol. In DMD trials, this approach can provide supplementary information about outcomes under specified treatment conditions, but excluding participants may introduce bias if deviations are related to outcomes.
• Percent of Normal DystrophinBiomarkers and Laboratory MeasurementsA way of expressing the amount of dystrophin detected in a patient's muscle compared with a defined normal reference. For example, 10% of normal indicates a measured level equivalent to one-tenth of that reference, not necessarily a 10% improvement in muscle function.
• Percent Predicted FVCSafety and Adverse Event TerminologyA person's measured forced vital capacity expressed as a percentage of the expected value for an appropriate reference population. In DMD, this measurement helps account for factors such as age, sex, and body size when assessing respiratory function, although interpretation depends on the reference equations used.
• Performance of Upper Limb (PUL)NSAA and Functional Assessment TerminologyA standardized assessment designed to measure upper-limb function in people with DMD. It evaluates activities involving different parts of the arm, including shoulder, elbow, and distal function, helping researchers monitor changes as the disease progresses.
• Performance-Based Outcome AssessmentNSAA and Functional Assessment TerminologyAn evaluation in which participants perform standardized tasks while an assessor measures their ability, speed, or quality of performance. DMD clinical trials use these assessments to quantify motor function and determine whether a treatment affects abilities relevant to everyday life.
• Pharmacodynamic BiomarkerBiomarkers and Laboratory MeasurementsA measurable biological indicator used to determine whether a treatment produces an expected effect in the body. In DMD research, pharmacodynamic biomarkers may include dystrophin expression or changes in biological pathways, helping researchers understand treatment activity before clinical benefits are established.
• Pharmacodynamics (PD)Biomarkers and Laboratory MeasurementsThe study of how a treatment affects the body, including its biological activity and measurable effects. In DMD research, pharmacodynamic assessments may investigate whether a drug influences its intended target, changes dystrophin production, or alters another disease-related biological process.
• Pharmacokinetics (PK)Biomarkers and Laboratory MeasurementsThe study of how a drug enters the body, moves through tissues, is metabolized, and is eliminated over time. In DMD trials, pharmacokinetic measurements help researchers understand drug exposure, establish dosing schedules, and investigate relationships between exposure, safety, and treatment response.
• Phase 1 TrialClinical Trial Design and Research TerminologyAn early-stage clinical study that primarily evaluates a treatment's safety, tolerability, and how the body processes it. In DMD, Phase 1 studies may also assess dose levels, biological activity, or preliminary biomarkers, but they are generally not designed to establish definitive clinical benefit.
• Phase 2 TrialClinical Trial Design and Research TerminologyA clinical study that explores a treatment's safety, dosing, and preliminary evidence of effectiveness in people with the target condition. In DMD, Phase 2 trials may assess functional outcomes, biomarkers, and dose-response relationships to help determine whether larger studies are justified.
• Phase 3 TrialClinical Trial Design and Research TerminologyA larger clinical study designed to evaluate a treatment's efficacy and safety in a defined patient population. DMD Phase 3 trials commonly compare treatment with placebo or another control and assess prespecified endpoints intended to support regulatory decisions.
• Phase 4 TrialClinical Trial Design and Research TerminologyA study conducted after a treatment has received marketing authorization. It may investigate long-term safety, effectiveness in routine practice, uncommon adverse events, or additional clinical questions that were not fully answered during earlier DMD treatment development.
• PhenotypeDuchenne Muscular Dystrophy: Disease TerminologyThe observable characteristics of a condition, including symptoms, physical abilities, and clinical findings. In DMD, the phenotype can vary according to the genetic mutation, age, disease stage, treatment history, and individual differences in disease progression.
• Phosphorodiamidate Morpholino Oligomer (PMO)DMD Treatment and Therapeutic ApproachesA type of synthetic antisense oligonucleotide designed to bind specific RNA sequences and influence RNA processing. Several DMD exon-skipping treatments use PMO chemistry to target selected exons, but the resulting dystrophin production and clinical effects vary by treatment and mutation.
• PhysiotherapyDMD Treatment and Therapeutic ApproachesA healthcare intervention involving movement, exercise, positioning, and other techniques to help maintain physical function and manage complications. In DMD, individualized physiotherapy can support joint mobility, flexibility, and participation in daily activities while avoiding inappropriate exercise intensity.
• PlaceboClinical Trial Design and Research TerminologyA treatment designed to resemble the investigational treatment but without its active therapeutic component. In DMD trials, placebo groups help researchers distinguish treatment effects from changes associated with expectations, natural disease progression, or other factors.
• Placebo-Controlled TrialClinical Trial Design and Research TerminologyA clinical study that compares an investigational treatment with a placebo under defined conditions. This design can help estimate the treatment's effects beyond those seen in the control group, provided that randomization, blinding, follow-up, and outcome assessment are appropriately conducted.
• Point MutationDuchenne Muscular Dystrophy: Disease TerminologyA genetic change involving a single DNA nucleotide. In the DMD gene, some point mutations create premature stop signals or alter essential protein sequences, preventing the production of normal dystrophin and potentially causing Duchenne muscular dystrophy.
• Post Hoc AnalysisClinical Trial Endpoints and Statistical AnalysisAn analysis conducted after the original study plan or primary results have been examined. In DMD research, post hoc analyses can generate useful hypotheses, but they are generally less conclusive than prespecified analyses because multiple comparisons and data-driven choices can increase the risk of misleading findings.
• Post-Marketing SurveillanceRegulatory and Drug Development TerminologyThe ongoing collection and assessment of safety information after a treatment becomes available for clinical use. In DMD, post-marketing surveillance can help identify uncommon or delayed adverse events and improve understanding of treatment safety in broader populations.
• Preclinical StudyAdvanced Clinical Research and Emerging Treatment ConceptsResearch conducted before a treatment is evaluated in human clinical trials, often using laboratory experiments and animal models. In DMD, preclinical studies may assess biological mechanisms, delivery, preliminary safety, and potential efficacy, but their results do not guarantee success in humans.
• PrednisoloneDMD Treatment and Therapeutic ApproachesA corticosteroid closely related to prednisone and used to manage Duchenne muscular dystrophy. It may help maintain motor function and delay aspects of disease progression, but its long-term use requires monitoring for adverse effects and individualized medical supervision.
• PrednisoneDMD Treatment and Therapeutic ApproachesA corticosteroid used in DMD management to help preserve muscle function and delay certain disease milestones. Its potential benefits must be balanced against adverse effects, which can include weight gain, behavioral changes, reduced bone health, growth effects, and metabolic complications.
• Primary EndpointClinical Trial Endpoints and Statistical AnalysisThe main outcome specified in a clinical trial to evaluate the treatment's intended effect. In DMD, the primary endpoint may involve a functional assessment or another predefined measure, and the trial's statistical analysis is generally designed around this principal outcome.
• Principal Investigator (PI)Clinical Trial Design and Research TerminologyThe qualified researcher responsible for the conduct of a clinical study at a particular site or, depending on the study structure, for overall scientific oversight. The principal investigator helps ensure that the trial follows its protocol and applicable ethical and regulatory requirements.
• Priority ReviewRegulatory and Drug Development TerminologyA regulatory review designation that shortens the FDA's target review time for an application meeting specified criteria. In DMD, Priority Review can accelerate the agency's review process, but it does not lower the evidentiary standards required for the relevant approval decision.
• Progressive Muscle WeaknessDuchenne Muscular Dystrophy: Disease TerminologyA gradual decline in muscle strength over time, caused in DMD by ongoing muscle damage and inadequate functional dystrophin. It can affect walking, standing, climbing stairs, lifting objects, and eventually breathing and other essential functions.
• Proof of Concept (PoC)Advanced Clinical Research and Emerging Treatment ConceptsEvidence from an early study that supports the plausibility of a treatment's proposed mechanism or potential therapeutic effect. In DMD research, proof of concept may involve biological changes or preliminary clinical observations, but it does not establish definitive efficacy or regulatory approval.
• Protein ExpressionAdvanced Clinical Research and Emerging Treatment ConceptsThe process through which cells produce proteins using genetic instructions. In DMD research, investigators may measure the expression of dystrophin or other proteins to evaluate whether a treatment affects its intended biological target, while distinguishing expression levels from demonstrated clinical benefit.
• Protein LocalizationAdvanced Clinical Research and Emerging Treatment ConceptsThe distribution of a protein within cells or tissues. In DMD studies, researchers may examine whether dystrophin reaches the muscle-fiber membrane, because detecting a protein in a sample does not necessarily establish that it is correctly located or performing its normal function.
• Protocol AmendmentClinical Trial Design and Research TerminologyA formally documented change to an approved or active clinical study protocol. Amendments may modify eligibility criteria, study procedures, endpoints, or other elements, and significant changes generally require appropriate regulatory and ethics review before implementation.
• PUL 2.0NSAA and Functional Assessment TerminologyAn updated version of the Performance of Upper Limb assessment used to evaluate upper-limb abilities in DMD. It includes tasks addressing different levels of arm function and helps researchers identify changes in performance, particularly in individuals who are no longer ambulatory.

R

• RandomizationClinical Trial Design and Research TerminologyThe assignment of participants to study groups using a chance-based process specified in the protocol. Randomization helps balance known and unknown characteristics between groups, reducing selection bias and strengthening the reliability of comparisons in DMD clinical trials.
• Randomized Controlled Trial (RCT)Clinical Trial Design and Research TerminologyA clinical study in which participants are assigned by chance to different treatment groups, often including an investigational treatment and a control. Randomization helps reduce selection bias and supports a more reliable comparison of treatment outcomes in DMD.
• Range of Motion (ROM)Respiratory, Cardiac, and Musculoskeletal TerminologyThe extent to which a joint can move through its available movement arc. In DMD, measuring range of motion can help identify developing contractures and monitor musculoskeletal changes, supporting decisions about stretching, positioning, orthotic use, and other interventions.
• Rare Pediatric Disease Designation (RPDD)Regulatory and Drug Development TerminologyA designation available under applicable regulatory rules for certain serious or life-threatening diseases primarily affecting children and meeting rarity criteria. In DMD development, designation may create eligibility for particular incentives, but it is not evidence of treatment efficacy or approval.
• Reading FrameDuchenne Muscular Dystrophy: Disease TerminologyThe way a genetic sequence is divided into groups of three nucleotides, called codons, during protein production. If a DMD mutation disrupts this frame, the resulting dystrophin may be prematurely truncated or absent; preserving the frame can sometimes permit a shorter protein.
• Reading Frame RestorationAdvanced Clinical Research and Emerging Treatment ConceptsThe recovery of an appropriate three-nucleotide reading frame during dystrophin production after a genetic or RNA-processing intervention. In DMD, some exon-skipping or gene-editing strategies aim to restore the frame, potentially allowing production of a shorter dystrophin protein.
• Readthrough TherapyDMD Treatment and Therapeutic ApproachesA treatment strategy intended to encourage cellular machinery to bypass certain premature stop signals in messenger RNA. In DMD caused by eligible nonsense mutations, readthrough approaches aim to restore production of a longer dystrophin protein, although efficacy and safety require clinical evaluation.
• Real-World Data (RWD)Clinical Trial Endpoints and Statistical AnalysisInformation about patients' health status and healthcare experiences collected during routine practice, such as electronic health records, registries, or insurance claims. In DMD research, these data can complement clinical trials but may contain missing information, inconsistent measurements, and confounding factors.
• Real-World Evidence (RWE)Clinical Trial Endpoints and Statistical AnalysisClinical evidence derived from data collected during routine healthcare or other real-world settings rather than exclusively from conventional clinical trials. In DMD, such evidence may help researchers investigate long-term outcomes, treatment use, safety, and effectiveness in broader patient populations.
• Recommended Phase 2 Dose (RP2D)Clinical Trial Design and Research TerminologyThe dose selected for further evaluation in later-stage clinical studies based on available safety, pharmacokinetic, pharmacodynamic, and other relevant evidence. In DMD development, selecting this dose involves balancing potential therapeutic activity with tolerability and the risks of treatment.
• Recruiting TrialClinical Trial Data, Access, and ReportingA clinical study that is actively seeking eligible participants. For DMD families, recruitment status should be checked alongside age requirements, genetic eligibility, location, and contact details because a study listed as recruiting may not have an available place at every site.
• RecruitmentClinical Trial Design and Research TerminologyThe process of identifying and inviting eligible people to consider participating in a clinical study. Recruitment speed in DMD trials may depend on age restrictions, mutation eligibility, geographic access, family awareness, site availability, and the practical burden of study visits.
• Recruitment StatusClinical Trial Data, Access, and ReportingThe current enrollment state of a clinical trial, as recorded by the sponsor or registry. Common statuses include recruiting, not yet recruiting, active but not recruiting, suspended, terminated, and completed, although the exact terminology depends on the registry.
• Regulatory ApprovalRegulatory and Drug Development TerminologyAuthorization granted by a relevant regulatory authority to market a treatment for specified uses and populations. In DMD, approval decisions depend on the available evidence, benefit-risk assessment, applicable legal standards, and the particular indication and jurisdiction.
• Regulatory SubmissionRegulatory and Drug Development TerminologyA formal package of information provided to a regulatory authority for review of a treatment or proposed clinical development activity. In DMD, submissions may concern permission to begin studies, changes to a trial, or an application for marketing authorization.
• Relative ChangeClinical Trial Endpoints and Statistical AnalysisThe change in a measurement expressed as a proportion or percentage of a reference value, often baseline. In DMD studies, relative changes can help compare measurements with different starting values, but percentages may be misleading when baseline values are small or highly variable.
• RepresentativenessClinical Trial Data, Access, and ReportingThe degree to which a study population reflects the characteristics of the broader population to which the findings may be relevant. In DMD trials, representation across age groups, disease stages, geographic regions, and genetic variants can influence the applicability of the results.
• Respiratory FunctionSafety and Adverse Event TerminologyThe ability of the respiratory system to move air and support effective breathing. In DMD, progressive weakness of respiratory muscles can reduce lung volumes and cough effectiveness, making respiratory assessments important for monitoring disease progression and evaluating treatment effects.
• Respiratory Muscle WeaknessRespiratory, Cardiac, and Musculoskeletal TerminologyA reduction in the strength of muscles involved in breathing and coughing. In DMD, progressive weakness of the diaphragm and other respiratory muscles can reduce lung volumes, impair secretion clearance, and increase the risk of respiratory complications.
• Responder AnalysisAdvanced Clinical Research and Emerging Treatment ConceptsAn analysis that classifies participants according to whether they meet a predefined threshold for improvement or another outcome. In DMD trials, responder analyses can show how many participants reach a specified level of change, but conclusions depend on the threshold and the quality of the comparison.
• Risk-Benefit AssessmentRegulatory and Drug Development TerminologyAn evaluation of the potential benefits of a treatment in relation to its known and potential risks. In DMD, this assessment considers the seriousness of the disease, available alternatives, evidence of clinical benefit, treatment-related harms, and the needs of the intended patient population.
• RNA SplicingDuchenne Muscular Dystrophy: Disease TerminologyThe process by which introns are removed and exons are joined together to produce mature messenger RNA. Correct splicing is essential for dystrophin production, and exon-skipping therapies aim to alter this process in a controlled, mutation-specific way.
• RNA-Based TherapyDMD Treatment and Therapeutic ApproachesA treatment that acts on RNA molecules or their processing rather than directly correcting the DNA sequence. In DMD, RNA-based approaches include exon-skipping strategies that seek to alter dystrophin messenger RNA and enable production of a shorter protein.

S

• Safety ProfileSafety and Adverse Event TerminologyThe overall pattern of adverse events, laboratory changes, and other safety findings observed with a treatment. In DMD research, a safety profile must consider event severity, frequency, timing, potential causes, and duration of follow-up rather than relying on a single headline safety statement.
• Sample SizeClinical Trial Endpoints and Statistical AnalysisThe number of participants included or planned for a clinical study. In DMD trials, sample size affects statistical precision, the ability to detect treatment effects, and the reliability of safety assessments, while recruitment feasibility and the rarity of eligible mutations also influence study design.
• Satellite CellsDMD Genetics and Molecular BiologyMuscle-resident stem cells that contribute to muscle repair and regeneration after injury. In DMD, ongoing muscle damage places continuous demands on regenerative processes, and researchers investigate whether supporting satellite-cell activity could help preserve or restore muscle tissue.
• ScoliosisDMD Treatment and Therapeutic ApproachesAn abnormal sideways curvature of the spine that may develop in individuals with neuromuscular conditions. In DMD, scoliosis can become more relevant as muscle weakness progresses, particularly after loss of ambulation, and may require monitoring and individualized orthopedic management.
• ScreeningClinical Trial Design and Research TerminologyThe process of assessing a potential participant to determine whether they meet a study's eligibility criteria. In DMD trials, screening may include genetic confirmation, physical examinations, laboratory tests, cardiac assessments, and reviews of medication history before enrollment.
• Secondary EndpointClinical Trial Endpoints and Statistical AnalysisAn additional outcome used to provide further information about a treatment's effects beyond the primary endpoint. DMD trials may assess secondary endpoints such as timed function tests, biomarkers, upper-limb function, or safety measures to build a broader understanding of the intervention.
• Serious Adverse Event (SAE)Safety and Adverse Event TerminologyAn adverse event meeting regulatory seriousness criteria, such as death, a life-threatening event, hospitalization, significant disability, or another medically important outcome. Seriousness is distinct from severity, and an SAE is not automatically caused by the investigational treatment.
• SeriousnessSafety and Adverse Event TerminologyA regulatory classification based on an adverse event's consequences, such as hospitalization, life-threatening illness, or death. A serious event may not be the most intense symptom experienced, and a severe symptom does not automatically meet the criteria for seriousness.
• SeveritySafety and Adverse Event TerminologyThe intensity or degree of an adverse event or medical symptom. Clinical trials often classify events as mild, moderate, or severe using defined criteria, but severity does not necessarily determine whether an event meets the separate regulatory definition of a serious adverse event.
• Single-Blind StudyClinical Trial Design and Research TerminologyA study in which one specified group, such as participants or investigators, is unaware of treatment assignment. The exact arrangement depends on the protocol, and the degree of blinding can influence how reliably treatment outcomes are assessed and compared.
• Six-Minute Walk Distance (6MWD)NSAA and Functional Assessment TerminologyThe total distance a participant covers during the six-minute walk test. Researchers use this measurement to compare walking capacity across visits or treatment groups, but changes must be interpreted in the context of baseline function, natural history, and testing variability.
• Six-Minute Walk Test (6MWT)NSAA and Functional Assessment TerminologyA standardized test measuring the distance a participant can walk in six minutes. In DMD clinical trials, it is used to assess walking capacity and endurance in ambulatory participants, with results influenced by age, motivation, fatigue, and disease severity.
• Six-Minute Walk Test VariabilityNSAA and Functional Assessment TerminologyThe differences in walking distance that may occur between repeated six-minute walk tests. These differences can arise from fatigue, motivation, health status, learning effects, or measurement conditions, so researchers consider variability when interpreting treatment-related changes.
• SpirometryRespiratory, Cardiac, and Musculoskeletal TerminologyA breathing test that measures how much air a person can inhale and exhale and how quickly it moves. In DMD, spirometry is commonly used to monitor respiratory function, including forced vital capacity, and can help identify changes associated with respiratory muscle weakness.
• Standard of CareDMD Treatment and Therapeutic ApproachesThe accepted approach to managing a condition based on available evidence, clinical guidance, and professional practice. In DMD, standard care typically involves multidisciplinary monitoring, corticosteroid management when appropriate, cardiac and respiratory surveillance, rehabilitation, and prevention or treatment of complications.
• Statistical PowerClinical Trial Endpoints and Statistical AnalysisThe probability that a study will detect a specified effect if that effect truly exists, under the assumptions used in its design. DMD trials require appropriate power calculations because small samples, variable disease progression, and insensitive endpoints can make treatment effects difficult to detect.
• Statistical SignificanceClinical Trial Endpoints and Statistical AnalysisA statistical judgment based on whether study data are sufficiently inconsistent with a specified null hypothesis under the chosen analysis. A statistically significant DMD trial result does not automatically establish a meaningful clinical benefit, and it must be interpreted alongside effect size and study quality.
• Stem Cell TherapyDMD Treatment and Therapeutic ApproachesA treatment approach involving stem cells, which can develop into specialized cell types or influence tissue repair through biological signaling. In DMD, researchers are exploring potential applications in muscle regeneration, but experimental concepts should not be confused with proven treatments or established clinical benefits.
• Study ArmClinical Trial Design and Research TerminologyA group of participants assigned to a particular treatment, dose, or comparison condition within a clinical trial. DMD studies may include several arms to evaluate different dose levels, treatment combinations, or a comparison between an investigational intervention and a control.
• Study CompletionClinical Trial Design and Research TerminologyThe point at which a participant has finished the required study procedures or the trial has reached its planned conclusion, depending on the context. Completion does not necessarily mean that the investigational treatment was effective or that every participant received the full intended treatment.
• Study ProtocolClinical Trial Design and Research TerminologyThe formal document describing a clinical study's objectives, design, eligibility criteria, interventions, assessments, and statistical methods. For DMD trials, the protocol specifies how safety and efficacy will be measured and establishes the procedures needed for consistent study conduct.
• Study SiteClinical Trial Design and Research TerminologyA hospital, research center, clinic, or other location where a clinical trial is conducted. DMD studies may involve multiple sites across different countries, and site selection can influence recruitment, participant diversity, access to specialist care, and the practical conduct of the study.
• Study SponsorClinical Trial Design and Research TerminologyThe individual, company, institution, or organization responsible for initiating and managing a clinical study. In DMD research, sponsors may be biotechnology companies, pharmaceutical companies, academic institutions, or other organizations responsible for study oversight and reporting.
• Study WithdrawalSafety and Adverse Event TerminologyThe departure of a participant from further study participation, which may include stopping treatment or ending some or all study assessments. In DMD research, withdrawal reasons and subsequent follow-up can affect the completeness of safety and efficacy data.
• Subgroup AnalysisClinical Trial Endpoints and Statistical AnalysisAn analysis examining treatment outcomes within a defined subset of study participants, such as an age range or functional category. In DMD research, subgroup analyses may identify differences in treatment response, but findings require caution, particularly when the analysis was not planned in advance.
• Supportive CareDMD Treatment and Therapeutic ApproachesHealthcare intended to maintain function, comfort, independence, and overall well-being while managing the effects of a disease. In DMD, supportive care includes physiotherapy, respiratory support, cardiac management, nutritional care, bone-health monitoring, and appropriate assistive technologies.
• Surrogate EndpointBiomarkers and Laboratory MeasurementsA measurement used in place of a direct clinical outcome because it is expected to predict a meaningful benefit. In DMD, dystrophin measurements may be considered in this context, but an increase in a surrogate marker does not automatically establish improved mobility, quality of life, or survival.
• Symptomatic TreatmentDMD Treatment and Therapeutic ApproachesA treatment intended to manage symptoms or complications without necessarily correcting the underlying genetic cause of DMD. Examples include medications for cardiac complications, respiratory support, physiotherapy, and treatments addressing pain or other health problems associated with disease progression.
• Systemic Gene DeliveryDMD Treatment and Therapeutic ApproachesThe administration of genetic material through a route intended to distribute it throughout the body rather than to one localized site. In DMD gene therapy, systemic delivery aims to reach multiple skeletal muscles and potentially the heart, but distribution, dose, and safety remain important considerations.

T

• T2 MappingBiomarkers and Laboratory MeasurementsAn MRI technique that measures the transverse relaxation time of tissue and can reflect changes in muscle composition, including inflammation and fat infiltration. In DMD research, T2 measurements may help track muscle abnormalities, although interpretation depends on the imaging method and disease stage.
• Target EngagementBiomarkers and Laboratory MeasurementsEvidence that a treatment interacts with its intended biological target in the body. In DMD research, target engagement may show that a drug reaches the relevant tissue or alters a specific molecular process, but it does not by itself demonstrate improved muscle function or patient outcomes.
• Target ProteinAdvanced Clinical Research and Emerging Treatment ConceptsA protein that a treatment is designed to influence, replace, inhibit, activate, or otherwise modify. In DMD research, the target may be dystrophin itself or another protein involved in muscle growth, inflammation, degeneration, or regeneration.
• Targeted TherapyAdvanced Clinical Research and Emerging Treatment ConceptsA treatment designed to act on a particular molecular target, genetic feature, or biological pathway. In DMD, some therapies target specific exon mutations, while others aim to modify disease-related processes shared by a broader range of patients.
• Ten-Meter Walk/Run Test (10MWR)NSAA and Functional Assessment TerminologyA timed functional assessment that measures how long a participant takes to walk or run a distance of 10 meters, according to the study's protocol. It is used in DMD research to evaluate mobility and monitor changes in walking or running performance.
• Therapeutic BenefitAdvanced Clinical Research and Emerging Treatment ConceptsAn improvement in health, function, symptoms, or another clinically relevant outcome attributable to treatment. In DMD, a potential therapeutic benefit should be evaluated using reliable evidence and should not be inferred solely from a company's biological claims or a single laboratory result.
• Therapeutic WindowAdvanced Clinical Research and Emerging Treatment ConceptsThe range of doses or treatment exposures within which a therapy may produce beneficial effects without unacceptable toxicity. In DMD research, defining the therapeutic window helps investigators balance potential efficacy with safety, particularly for treatments involving systemic delivery or immune-related risks.
• Time to Climb Four StairsNSAA and Functional Assessment TerminologyA timed assessment that records how long a participant takes to ascend a standardized flight of four stairs. It evaluates lower-limb strength, coordination, and functional mobility and may help researchers detect changes in motor performance during DMD clinical trials.
• Time to Descend Four StairsNSAA and Functional Assessment TerminologyA timed assessment that measures how quickly a participant descends a standardized set of four stairs. The task evaluates functional mobility and lower-limb control, and changes in performance may reflect disease progression, although results are affected by technique and testing conditions.
• Time to Rise from Floor (TTRF)NSAA and Functional Assessment TerminologyA timed assessment that measures how long a participant takes to move from the floor to a standing position. In DMD, this task can become slower as proximal muscle weakness progresses, making changes in completion time useful for tracking functional performance.
• Time-to-Event EndpointClinical Trial Endpoints and Statistical AnalysisAn outcome measuring the time until a specified event occurs after a defined starting point. In DMD studies, this may include the time until loss of ambulation or another clinically meaningful milestone, allowing researchers to compare how long participants maintain a particular ability.
• Timed Function Tests (TFTs)NSAA and Functional Assessment TerminologyA group of assessments that measure how long a participant takes to complete specific physical activities. DMD trials may include timed walking or running, rising from the floor, and stair climbing to quantify motor performance and changes in mobility over time.
• Timed Rise from FloorNSAA and Functional Assessment TerminologyA functional test that measures the time required for a participant to stand up from a lying or floor-level position. In DMD, difficulty with this movement can reflect proximal muscle weakness, and the test is often used to monitor changes in motor function.
• Topline ResultsClinical Trial Endpoints and Statistical AnalysisA company's initial summary of selected clinical trial findings, often released before a full technical report or scientific publication. In DMD research, topline announcements may omit detailed biomarker data, statistical methods, individual outcomes, or important safety information needed for independent evaluation.
• Translational ResearchAdvanced Clinical Research and Emerging Treatment ConceptsResearch that connects laboratory discoveries with potential applications in human healthcare. In DMD, translational research may investigate how findings from cells or animal models can inform treatment development, clinical trial design, biomarker selection, and the evaluation of therapeutic strategies.
• Treatment AccessClinical Trial Data, Access, and ReportingThe practical ability of an eligible patient to obtain and use a treatment. In DMD, access may depend on regulatory approval, reimbursement, cost, availability of specialist care, genetic eligibility, and healthcare-system policies, even when a treatment is authorized in another country.
• Treatment BurdenClinical Trial Data, Access, and ReportingThe combined demands that a treatment places on patients and caregivers, including administration, monitoring, travel, hospital visits, and management of adverse effects. In DMD, treatment burden is relevant when comparing approaches that differ in dosing schedules, delivery methods, or follow-up requirements.
• Treatment DiscontinuationSafety and Adverse Event TerminologyThe permanent stopping of a study treatment before the planned end of therapy. In DMD trials, discontinuation may occur because of adverse events, lack of perceived benefit, participant choice, protocol requirements, or other reasons that should be clearly reported.
• Treatment EffectClinical Trial Endpoints and Statistical AnalysisThe difference in an outcome attributable to the intervention under investigation, as estimated using the study's design and analysis. In DMD trials, treatment effects may be expressed as differences in functional scores, walking distance, biomarker levels, or other predefined measurements.
• Treatment FailureClinical Trial Data, Access, and ReportingA predefined situation in which a treatment does not achieve its intended objective or is stopped because of insufficient benefit, unacceptable risks, or other specified criteria. In DMD trials, the meaning of treatment failure depends on the protocol and should not be inferred from one isolated measurement.
• Treatment GroupClinical Trial Design and Research TerminologyThe group of participants receiving the investigational intervention being evaluated. In DMD trials, researchers compare outcomes in the treatment group with those in a control group to assess differences in safety, biomarkers, motor function, or other predefined endpoints.
• Treatment ResponseAdvanced Clinical Research and Emerging Treatment ConceptsA measurable change following administration of a treatment, assessed using predefined biological, clinical, or safety measures. In DMD trials, a response may involve changes in dystrophin levels or functional outcomes, but the significance depends on the magnitude, duration, and clinical relevance of the findings.
• Treatment-Emergent Adverse Event (TEAE)Safety and Adverse Event TerminologyAn adverse event that begins after treatment starts or worsens after treatment initiation, according to the study's predefined criteria. TEAEs are commonly reported in clinical trials, but their occurrence alone does not establish that the treatment caused the event.
• Treatment-Related Adverse EventSafety and Adverse Event TerminologyAn adverse event that investigators or study reviewers consider to have a possible or established relationship with the investigational treatment. Assessing causality can be difficult because symptoms may arise from the underlying disease, other medications, unrelated illnesses, or study procedures.
• Trial RegistrationClinical Trial Data, Access, and ReportingThe process of entering specified information about a clinical study into a public registry. Registration helps improve transparency by documenting a trial's objectives, design, endpoints, and other information, making it easier to compare the original study plan with its reported findings.
• Trial SuspensionClinical Trial Data, Access, and ReportingA temporary pause in some or all clinical trial activities. In DMD research, a suspension may occur because of a safety concern, regulatory action, or operational issue, and the reasons, scope, and conditions for restarting depend on the particular study.
• Trial TerminationClinical Trial Data, Access, and ReportingThe early stopping of a clinical study before its planned completion. A DMD trial may be terminated because of safety concerns, recruitment difficulties, business decisions, insufficient evidence of benefit, or other reasons; termination alone does not establish the specific reason or outcome.

U

• Unmet Medical NeedClinical Trial Data, Access, and ReportingA health need that existing treatments or healthcare services do not adequately address. In DMD, unmet needs may include slowing disease progression, improving treatment safety, preserving motor function, extending benefits to additional mutations, and ensuring affordable access to effective therapies.
• Unmet Treatment NeedAdvanced Clinical Research and Emerging Treatment ConceptsA need for better therapeutic options because current treatments do not adequately address a particular aspect of a disease. In DMD, unmet treatment needs include slowing progression, improving long-term outcomes, reducing treatment risks, expanding mutation eligibility, and ensuring equitable access.
• Upper Limb FunctionNSAA and Functional Assessment TerminologyThe ability to perform activities involving the shoulders, arms, hands, and fingers. As DMD progresses, upper-limb assessments become increasingly important for understanding independence, daily activities, and the effects of treatment in individuals who have lost ambulation.
• Utrophin (Paralogue of Dystrophin)DMD Treatment and Therapeutic ApproachesIn Duchenne Muscular Dystrophy (DMD), utrophin acts as a natural structural surrogate or "backup" protein that can functionally compensate for the lack of dystrophin. It is one of the most promising targets for mutation-independent therapeutic development.

V

• Vamorolone (Agamree)DMD Treatment and Therapeutic ApproachesA steroidal anti-inflammatory medicine developed to treat DMD while aiming to modify some adverse effects associated with traditional corticosteroids. Its effects on motor function, growth, bone health, and other outcomes must be interpreted using clinical trial evidence and applicable treatment guidance.
• Vertebral FractureRespiratory, Cardiac, and Musculoskeletal TerminologyA break or compression injury involving one or more bones of the spine. In DMD, vertebral fractures can occur in the context of reduced bone strength and corticosteroid exposure, sometimes without obvious symptoms, making appropriate bone-health assessment important.
• Viral VectorDMD Genetics and Molecular BiologyAn engineered virus-based delivery system used to transport genetic material into target cells. In DMD gene therapy, viral vectors may help deliver instructions for therapeutic proteins, but researchers must evaluate tissue targeting, immune reactions, dose-related risks, and the duration of expression.
• Vital SignsSafety and Adverse Event TerminologyBasic clinical measurements used to assess a person's physiological condition, commonly including heart rate, blood pressure, respiratory rate, and body temperature. DMD trials may monitor vital signs at scheduled visits to identify changes that could indicate adverse effects or other health concerns.

W

• Western BlotDMD Genetics and Molecular BiologyA laboratory technique used to detect and estimate the amount and molecular size of a specific protein in a biological sample. In DMD trials, Western blot may quantify dystrophin relative to a reference standard, although results depend on sample preparation and normalization methods.
• Within-Group ChangeClinical Trial Endpoints and Statistical AnalysisThe difference between measurements obtained from the same study group at different time points. In DMD trials, within-group improvement or stability may be informative, but it does not independently establish treatment benefit without appropriate comparison and consideration of expected disease progression.

X

• X-Linked Recessive InheritanceDuchenne Muscular Dystrophy: Disease TerminologyA pattern of inheritance associated with mutations in genes located on the X chromosome. DMD primarily affects boys because they usually have one X chromosome, while females with a DMD gene variant may be carriers and can also develop symptoms.